Psilocybin-assisted therapy is legal in three states, but access has so far been limited and expensive.
Category: Food and Drug Administration
-
‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech World
The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.
-
F.D.A. Turmoil Keeps Spotlight on Its Commissioner
The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.
-
F.D.A. Approves Two New Drugs to Treat Gonorrhea
The sexually transmitted disease has become increasingly resistant to existing antibiotics.
-
FDA Expands Covid Vaccine Inquiry to Adult Deaths
The agency claimed that 10 children’s deaths were linked to the shots, although it did not release evidence to support the assertions.
-
F.D.A. Attributes 10 Children’s Deaths to Covid Vaccines
The agency’s top vaccine regulator said that a review had found that the children were likely to have died “because of” the shots. But public health experts want to examine the data.
-
Botulism Bacteria Found in Infant Formula, ByHeart Confirms
ByHeart, the maker of the product, has been linked to an outbreak of illnesses among infants that led to their hospitalizations.
-
F.D.A. Sharply Limits Use of Drug Linked to Two Teen Deaths
A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Infant Formula Recalled Amid Botulism Investigation
Health agencies asked caregivers to stop using two batches of ByHeart Whole Nutrition Infant Formula after they found an increase in cases of infant botulism.
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.